default author photo

Cristina Reboredo Rendo

Instituto de Investigación Biomédica de A Coruña - Complexo Hospitalario Universitario A Coruña

SCHOLARLY PAPERS

2

DOWNLOADS

114

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Prevention of Sacituzumab Govitecan-Related Neutropenia and Diarrhea in Patients with Her2-Negative Advanced Breast Cancer (PRIMED): An Open-Label, Single-Arm, Phase 2 Trial

Number of pages: 21 Posted: 17 Mar 2025
José Manuel Pérez-García, Maria Gion, Manuel Ruiz Borrego, Isabel Blancas, Elena López-Miranda, Salvador Blanch, Sabela Recalde, Cristina Reboredo Rendo, Xavier González, Nerea Ancizar, Serafin Morales, Patricia Cortez, Zuzanna Piwowarska, Eileen Shimizu, José Antonio Guerrero, Miguel Sampayo-Cordero, Alejandro Martínez-Bueno, Javier Cortés and Antonio Llombart-Cussac
Quiron Group - International Breast Cancer Center (IBCC), Medica Scientia Innovation Research (MEDSIR), Hospital Universitario Virgen del Rocío - Medical Oncology Department, Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Complex Hospitalari Universitari Moisès Broggi, Instituto de Investigación Biomédica de A Coruña - Complexo Hospitalario Universitario A Coruña, Hospital Universitario General de Catalunya, Hospital Universitario Donostia, Hospital Universitari Arnau de Vilanova, Hospital Beata Maria Ana de Jesus, Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Hospital Universitario Dexeus, Vall d'Hebron Institute of Oncology and Medica Scientia Innovation Research (MEDSIR)
Downloads 96 (709,832)

Abstract:

Loading...

Sacituzumab govitecan, triple-negative, hormone receptor-positive/HER2-negative, neutropenia, diarrhea, advanced breast cancer, loperamide, granulocyte-colony stimulating factor, G-CSF.

2.

HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from a Real-World Cohort

Number of pages: 35 Posted: 11 Feb 2026
beatriz Alonso de castro, Sandra Cobo, María Alonso Pena, Julia Pérez Malillos, Cristina Reboredo Rendo, Eva Pérez López, Oleguer Castillo, Valeria Sirenko, Angela Aguirre, Paula Blasco, Lourdes Calvo Martínez, Patricia Galván, Esther Sanfeliu, Paula Saavedra Nieves, Ángel Concha López, Aleix Prat, Fara Brasó-Maristany and Silvia Antolín Novoa
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Instituto de Investigación Biomédica de A Coruña - Complexo Hospitalario Universitario A Coruña, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital Clinic of Barcelona - Department of Medical Oncology, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 18 (1,481,165)

Abstract:

Loading...

HER2, Breast Cancer, HER2DX, trastuzumab, pertuzumab, Pathological complete response, neoadjuvant